Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of health economics and outcomes researchOpen Access

Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDavid WaterhouseThe US Oncology NetworkILI. А. LiMoscow Clinical Scientific CenterLMLaura MorrisonGroup for Research in Decision Analysis

Discussion

Loading...

Member takes

Overview

Analysis reveals increasing costs and resource utilization across treatment lines in patients with EGFRm NSCLC, indicating healthcare challenges.

Key Points

  • Each successive line of therapy in advanced non-small cell lung cancer was shorter and more costly.
  • Mean all-cause costs per patient per month were $27,751 in first-line therapy and increased in subsequent lines.
  • Patients receiving osimertinib monotherapy had higher outpatient visits, with 4.79 visits per patient per month in first-line.
  • Findings underscore the need for effective first-line treatments to manage costs and improve patient outcomes.

Cite This Study

Waterhouse et al. (2025) studied this question.

synapsesocial.com/papers/68c1d80554b1d3bfb60fa7c8https://doi.org/10.36469/001c.142771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC2019 · 2,937 citations
  2. 2Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies2021 · 148 citations
  3. 3Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis2023 · 11 citations
  4. 4Optimizing Outcomes and Treatment Sequences in <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Recent Updates2019 · 29 citations
  5. 5Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer2018 · 6,764 citations